Networks of innovation : vaccine development at Merck, Sharp & Dohme, and Mulford, 1895-1995 / Louis Galambos with Jane Eliot Sewell.
Language: English Publication details: Cambridge : Cambridge University Press, 1995. Description: xi, 273 p., [4] p. of plates : ill. (some col.), portsISBN: 9780521563086 (hardback); 0521563089 (hardback)Subject(s): Merck, Sharp & Dohme International -- History -- 20th century | H. K. Mulford Company. -- History -- 19th-20th century | Sharp & Dohme -- History -- 20th century | Merck and Company -- History -- 20th century | Pharmaceutical Industry -- United States -- History -- 20th century | Vaccines -- History -- 19th-20th century | Pharmaceutical Companies -- History -- 19th-20th centurySummary: Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.| Item type | Current library | Call number | Status | Date due | Barcode | Item holds |
|---|---|---|---|---|---|---|
Book
|
RPS Library Basement Store | 615.45:625.12 MER (Browse shelf(Opens below)) | Available | 227971 |
Includes bibliographical references and index.
Networks of Innovation offers an historical perspective on the manner in which private-sector organizations have acquired, sustained, and periodically lost the ability to develop, manufacture, and market new serum antitoxins and vaccines. The primary focus is on the H. K. Mulford Company, on Sharp and Dohme, which acquired Mulford in 1929, and upon Merck & Co Inc., which merged with Sharp and Dohme in 1953. By surveying a century of innovation in biologicals, the authors are able to analyze the conditions that either promoted or prevented creative changes in this important industry. They show how the activities of these three commercial enterprises were related to a series of complex, evolving networks of scientific, governmental, and medical institutions in the United States and abroad. This is the first such history to draw exclusively on sources internal to Merck, one of the world's leading innovators in modern vaccines and pharmaceuticals.
Previous Accession Number: AKLF. Previous Classmark: 615.45:615.12:615.371(09) MER.